Natural products and chronic hepatitis C virus

Liver International

Volumn 27, Issue 1, 2007, Pages 17-25

  Azzam, H S ^a   Goertz, C ^b   Fritts, M ^b   Jonas, W B ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SAMUELI INSTITUTE   (United States)

Author keywords

Alternative treatments; Chronic hepatitis C; Gomisin A; Lactoferrin; Natural products; Oxymatrine; Schisandra; TJ 108

Indexed keywords

ALPHA TOCOPHEROL; ANGELICA EXTRACT; ASCORBIC ACID; ASTRAGALUS EXTRACT; ATRACTYLODES EXTRACT; BING GAN LING; BING GAN NING; CINNAMON EXTRACT; CITRUS FRUIT EXTRACT; GINSENG EXTRACT; GLUTATHIONE; GLYCYRRHIZA EXTRACT; GOMISIN; GOMISIN A; HERBACEOUS AGENT; INTERFERON; LACTOFERRIN; MATRINE; NATURAL PRODUCT; OXYMATRINE; PAEONIA EXTRACT; PLANT MEDICINAL PRODUCT; REHMANNIA EXTRACT; SCHISANTHERIN D; SILYMARIN; THIOCTIC ACID; TJ 108; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN B GROUP; YI ZHU;

ABSENCE OF SIDE EFFECTS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; FATIGUE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; MONOTHERAPY; NONHUMAN; REVIEW; STANDARDIZATION; TREATMENT DURATION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; HEPATITIS C, CHRONIC; HUMANS; LACTOFERRIN;

EID: 33846423215     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01408.x     Document Type: Review

References (73)

1. WHO. Hepatitis C. Fact sheet No. 164 2000. Accessed at http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Kane A, Llyod J, Zaffran M, Simnson L, Kane M. Unsafe injections in the developing world: Region based estimates of the transmission of blood-borne pathogens. WHO Bull 1999; 77(10): 801-7.
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362(9401): 2095-100.
4. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15(1): 7-16.
5. Deuffic-Burban S. Comparing the Public Health Burden of Chronic Hepatitis C and HIV Infection in United States. In: 54th Annual Meeting of the American Association for the Study of Liver Diseases, 2003 October 24-28, Boston, MA, Abstract 552.
6. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28(4): 1161-5.
7. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut 2004; 53(5): 744-9.
8. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28(6): 930-8.
9. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132(4): 296-305.
10. Montalo G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci 2002; 963: 13-20.
11. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 Suppl. 1): S30-4.
12. NIH Consensus. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19(3): 1-46.
13. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140(6): 465-79.
14. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004; 39(2): 333-42.
15. Guyton KZ, Kensler TW. Prevention of liver cancer. Curr Oncol Rep 2002; 4(6): 464-70.
16. Nousbaum J. Genomic subtypes of hepatitis C virus: Epidemiology, diagnosis and clinical consequences. Bull Soc Pathol Exot 1998; 91(1): 29-33.
17. el-Zayada A, Selim O, Haddad S, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999; 31(6): 472-5.
18. WHO. WHO Traditional Medicine Strategy 2002-2005. In: 2002-2005. Available at: http://www.who.int/medicines/library/trm/ trmr_stat_eng.pdf. Accessed on June 18/04.
19. Frank C, Mohamad MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355(9207): 887-91.
20. Van Rossum TG, Vulto AG, de Man RA, et al. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998; 12(3): 199-205.
21. Seeff LB, Lindsay KL, Bacon BR, et al. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34(3): 595-603.
22. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt) 2001; 15 (10): 1267-72; discussion 1272-8, 1283.
23. Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 2002; 113(6): 506-15.
24. Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: A systematic review. J Hepatol 2004; 40(3): 491-500.
25. Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: A Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003; 98 (3): 538-44.
26. Chen XS, Wang GJ, Cai X, et al. Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol 2001; 7(1): 49-52.
27. Chen Y, Li J, Zeng M, et al. The inhibitory effect of oxymatrine on hepatitis C virus in vitro. Zhonghua Gan Zang Bing Za Zhi 2001;(9 Suppl.): 12-14.
28. Liu J, Liu Y, Klaassen CD. The effect of Chinese hepatoprotective medicines on experimental liver injury in mice. J Ethnopharmacol 1994; 42(3): 183-91.
29. Yang W, Zeng M, Fan Z, et al. Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2002; 10(3): 193-6.
30. Li J, Li C, Zeng M. Preliminary study on therapeutic effect of oxymatrine in treating patients with chronic hepatitis C. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998; 18(4): 227-9.
31. Dong Y, Xi H, Yu Y, et al. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: A study on the anti-hepatitis B virus mechanism of oxymatrine. J Gastroenterol Hepatol 2002; 17(12): 1299-306.
32. Wang BE. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 2000; (15 Suppl.): E67-70.
33. Yu YY, Wang QH, Zhu LM, et al. A clinical research on oxymatrine for the treatment of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2002; 10(4): 280-1.
34. Liu J, Zhu M, Shi R, Yang M. Radix Sophorae flavescentis for chronic hepatitis B: A systematic review of randomized trials. Am J Chin Med 2003; 31(3): 337-54.
35. Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol 2003; 9(11): 2480-3.
36. Mao YM, Zeng MD, Lu LG, et al. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: A randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 2004; 10(22): 3269-73.
37. Cyong JC, Ki SM, Iijima K, et al. Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 2000; 28(3-4): 351-60.
38. Natural Medicines Comprehensive Database. Schisandra Monograph.
39. Jellin JM (ed) Schisandra Monograph, in Natural Medicines Comprehensive Database, complied by the editors of Pharmacist's letter, Prescriber's letter. Stockton CA: Therapeutic Research Faculty.
40. Liu KT, Lesca P. Pharmacological properties of Dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schizandrae Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. Chem Biol Interact 1982; 41(1): 39-47.
41. Aoki T, Kojima T, Kameda N, et al. Anti-inflammatory effect of a traditional Chinese medicine, ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to), on alveolar macrophages stimulated by RANTES or TNF-alpha. Arerugi 1994; 43(5): 663-7.
42. Kamei T, Kumani H, Beppu K, et al. Response of healthy individuals to ninjin-yoei-to extract-enhancement of natural killer cell activity. Am J Chin Med 1998; 26(1): 91-95.
43. Nakada T, Watanabe K, Jin GB, et al. Effect of ninjin-youei-to on Th1/ Th2 type cytokine production in different mouse strains. Am J Chin Med 2002; 30(2-3): 215-23.
44. Ikegami F, Fujii Y, Ishihara K, Satoh T. Toxicological aspects of Kampo medicines in clinical use. Chem Biol Interact 2003; 145(3): 235-50.
45. Takayama F, Egashira T, Yamanaka Y. Protective effect of Ninjin-yoei-to on damage to isolated hepatocytes following transient exposure to tert-butyl hydroperoxide. Jpn J Pharmacol 2001; 85(3): 227-33.
46. Egashira T, Takayama F, Komatsu Y. Changes of materials that scavenge 1,1-diphenyl-2-picrylhydrazyl radicals in plasma by per-oral administration of Kampo medicine, Ninjin-yoei-to in rats. J Pharm Pharmacol 2003; 55 (3): 367-71.
47. Nagai H, Yakuo I, Aoki M, et al. The effect of gomisin A on immunologic liver injury in mice. Planta Med 1989; 55(1): 13-17.
48. Nomura M, Nakachiyama M, Hida T, et al. Gomisin A, a lignan component of Schizandora fruits, inhibits development of preneoplastic lesions in rat liver by 3′-methyl-4-dimethylamino-azobenzene. Cancer Lett 1994; 76(1): 11-18.
49. Nomura M, Ohtaki Y, Hida T, et al. Inhibition of early 3-methyl-4-dimethylaminoazobenzene-induced hepatocarcinogenesis by gomisin A in rats. Anticancer Res 1994; 14 (5A): 1967-71.
50. Shiota G, Yamada S, Kawasaki H. Rapid induction of hepatocyte growth factor mRNA after administration of gomisin A, a lignan component of shizandra fruits. Res Commun Mol Pathol Pharmacol 1996; 94 (2): 141-6.
51. Ohkura Y, Mizoguchi Y, Sakagami Y, et al. Inhibitory effect of TJN-101 ((+)-(6S,7S,R-biar)-5,6,7,8-tetrahydro-1,2,3,12-tetramethoxy -6,7-dimethyl-10,11- methylenedioxy-6-dibenzo[a,c]cyclooctenol) on immunologically induced liver injuries. Jpn J Pharmacol 1987; 44(2): 179-85.
52. Yamada S, Murawaki Y, Kawasaki H. Preventive effect of gomisin A, a lignan component of shizandra fruits, on acetaminophen-induced hepatotoxicity in rats. Biochem Pharmacol 1993; 46(6): 1081-5.
53. Kubo S, Ohkura Y, Mizoguchi Y, et al. Effect of Gomisin A (TJN-101) on liver regeneration. Planta Med 1992; 58(6): 489-92.
54. Takeda S, Arai I, Hasegawa M, et al. Effect of gomisin A (TJN-101), a lignan compound isolated from Schisandra fruits, on liver function in rats. Nippon Yakurigaku Zasshi 1988; 91(4): 237-44.
55. Maeda S, Takeda S, Miyamoto Y, et al. Effects of gomisin A on liver functions in hepatotoxic chemicals-treated rats. Jpn J Pharmacol 1985; 38(4): 347-53.
56. Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. J Clin Gastroenterol 2005; 39(8): 737-42.
57. Farnaud S, Evans RW. Lactoferrin-a multifunctional protein with antimicrobial properties. Mol Immunol 2003; 40(7): 395-405.
58. Lonnerdel B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003; 77(6): 1537S-43S.
59. Ishii K, Takamura N, Shinohara M, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003; 25(3): 226-33.
60. Tuccari G, Villari D, Giuffre G, et al. Immunohistochemical evidence of lactoferrin in hepatic biopsies of patients with viral or cryptogenetic chronic liver disease. Histol Histopathol 2002; 17(4): 1077-83.
61. Bonis PA, Chopra S. Investigational therapies for hepatitis C virus infection. In: UpToDate,H2003. Available at: http://www.uptodate.com. Accessed on June 16, 2004.
62. Hara K, Ikeda M, Saito S, et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 2002; 24(3): 228.
63. Ikeda M, Sugiyama K, Tanaka T, et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 1998; 245(2): 549-53.
64. Ikeda M, Nozakii A, Sugiyama K, et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 2000; 66(1): 51-63.
65. Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997; 71(8): 5997-6002.
66. Nozaki A, Ikeda M, Naganuma A, et al. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 2003; 278(12): 10162-73.
67. Nozaki A, Tanaka K, Naganuma A, Kato N. Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C. Nippon Rinsho 2002; 60(4): 819-29.
68. Tsuda H, Sekine K, Fujita K, Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies. Biochem Cell Biol 2002; 80(1): 131-6.
69. Yoo YC, Watanabe S, Watanabe R, et al. Bovine lactoferrin and lactoferricin inhibit tumor metastasis in mice. Adv Exp Med Biol 1998; 443: 285-91.
70. Tanaka K, Ikeda M, Nozaki A, et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study. Jpn J Cancer Res 1999; 90(4): 367-71.
71. Okada S, Tanaka K, Sato T, et al. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 2002; 93(9): 1063-9.
72. Iwasi M, Kaito M, Ikoma J, et al. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 2002; 97(3): 766-7.
73. Hirashima N, Orito E, Ohba K, et al. A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol Res 2004; 29 (1): 9-12.